

IN THE CLAIMS

Claims 1-17 (Canceled)

Claim 18 (Previously presented): A stent coated with 3-deazaadenosine or an analog of 3-deazaadenosine selected from the group consisting of a salt of 3-deazaadenosine and a precursor of 3-deazaadenosine which can be degraded to 3-deazaadenosine in the body under physiological conditions.

Claim 19 (Previously presented): The stent of claim 36, wherein said analog of deazaadenosine is selected from the group consisting of 3-deazaadenosine-3'-monophosphoric acid, 3-deazaadenosine-3'5'-cyclophosphate and 3-deazaadenosine-5'-diphosphoric acid.

Claim 20 (Previously presented): The stent of claim 36, wherein said 3-deazaadenosine or analog of 3-deazaadenosine is covalently bound to the stent.

Claim 21 (Previously presented): A method of preventing in-stent restenosis, reperfusion injuries or treating and preventing infectious and inflammatory coronary syndromes, dilated cardiomyopathy, viral myocarditis or infections by parasites by implanting the stent of claim 36 in a patient in need thereof.

Claim 22 (Previously presented): The method of claim 39, wherein the condition is in-stent restenosis.

Claim 23 . (new): A method for the prevention or treatment of diseases associated with expression of adhesion molecules ICAM-1 and VCAM-1 in endothelial cells in a patient comprising administering a 3-deazaadenosine or an analog of 3-deazaadenosine selected from the group consisting of a salt of 3-deazaadenosine and a precursor of 3-deazaadenosine which can be degraded to 3-deazaadenosine in the body under physiological conditions to a patient in need thereof.

Claim 24 (new): A method for the prevention or treatment of in stent restenosis in a patient comprising administering at least one of 3-deazaadenosine or an analog of 3-deazaadenosine selected from the group consisting of a salt of 3-deazaadenosine and a precursor of 3-deazaadenosine which can be degraded to 3-deazaadenosine in the body under physiological conditions to a patient in need of such prevention or treatment.

Claim 25 (new): The method of claim 24, wherein said analog of deazaadenosine is selected from the group consisting of 3-deazaadenosine-3'-monophosphoric acid, 3-deazaadenosine-3'5'-cyclophosphate and 3-deazaadenosine-5'-diphosphoric acid.